Blog
RSS FeedPosted by Michael Wonder on 23 Jun 2022
Industry sponsorship bias in cost effectiveness analysis: registry based analysis
22 June 2022 - The Tufts Cost-Effectiveness Analysis Registry was used to identify all CEAs published in Medline between 1976 and ...
Posted by Michael Wonder on 20 Dec 2021
Biased Outcome reporting Guidelines for Underwhelming Studies (BOGUS) statement and checklist
10 December 2021 - A light hearted article to end the year. Merry Christmas to all our readers. We will ...
Posted by Michael Wonder on 27 Nov 2021
Can we trust strong recommendations based on low quality evidence?
25 November 2021 - A necessary requirement for development of trustworthy guidelines is to respect the relation between the quality (certainty) ...
Posted by Michael Wonder on 15 Jun 2021
Health care funding decisions and real world benefits: reducing bias by matching untreated patients
14 June 2021 - Governments and health insurers often make funding decisions based on health gains from randomised controlled trials. ...
Posted by Michael Wonder on 14 Dec 2020
From publication bias to lost in information
11 December 2020 - In BMJ Evidence-Based Medicine, IQWiG researchers call for a central, public and worldwide portal for clinical ...
Posted by Michael Wonder on 18 Jan 2019
Patient groups fail to declare financial interests during NICE assessments
16 January 2019 - Patients’ groups involved in assessing treatments for the NHS often fail to disclose their financial interests, ...
Posted by Michael Wonder on 11 Jul 2018
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology
11 July 2018 - A primary outcome in oncology trials is overall survival. However, to estimate overall survival accurately requires ...
Posted by Michael Wonder on 14 Jun 2018
Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany
13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...
Posted by Michael Wonder on 13 Jun 2018
Metastatic breast cancer: highly selective post-hoc analysis rather than complete publication of quality of life data
13 June 2018 - IQWiG employees criticise the publication practice of PALOMA-2 study authors. ...
Posted by Michael Wonder on 05 Dec 2017
Canada's regulator of patented drug prices is rigging data, and risking our health
5 December 2017 - The patent medicine pricing board is making a blatant attempt to bias the data. ...
Posted by Michael Wonder on 26 Sep 2017
Drugs watchdog NICE attacks pharmaceutical industry in pricing dispute
25 September 2017 - Industry expert’s evidence is not independent, NICE argues. ...
Posted by Michael Wonder on 24 Jul 2017
Managing conflicts of interest – making good decisions
24 July 2017 - NICE is seeking views on a new conflicts of interest policy to ensure its committees’ decisions ...
Posted by Michael Wonder on 23 Jul 2017
Tackling submission and publication bias
17 July 2017 - Evoniuk and colleagues analysed whether submission and publication bias are based on study outcome. ...
Posted by Michael Wonder on 02 May 2017
Addressing bias and conflict of interest among biomedical researchers
2 May 2017 - Bias in research is ubiquitous and the goal of every researcher should be to reduce bias and ...
Posted by Michael Wonder on 20 Feb 2017
Big pharma funding biases drug trials in favour of a sponsor's product: review
21 February 2017 - Drug and device trial studies that are sponsored by the pharmaceutical industry are more likely to ...